BLITE-01: Standard Silicone-based vs. B-Lite® Light Weight Breast Implant After Total Mastectomy and Radiotherapy for Breast Cancer

Sponsor
Istituti Clinici Scientifici Maugeri SpA (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03737500
Collaborator
(none)
80
1
2
54
1.5

Study Details

Study Description

Brief Summary

Reconstructive surgery with breast implants after total mastectomy for breast cancer is invariably related to several possible complications, such as atrophy of surrounding tissues, skin thinning, capsular contracture, wound dehiscence and inframammary fold break. Such complications are promoted by elastic properties of tissues and their response to gravity forces exerted on breast implant weight, leading to microischaemic events. A poor cosmetic outcome may result up to breast implant exposure, and its removal may become necessary, thus compromising the quality of breast reconstruction. These complications are further favoured by post-mastectomy radiotherapy (PMRT), since irradiation could enhance microischaemia of peri-prosthetic soft tissues and muscle, with subsequent inadequate healing, fibrosis and thinning. Since PMRT has been associated to improved loco-regional control in node-positive breast cancer patients, its use has increased in recent years. On one hand, PMRT has improved loco-regional control but, on the other hand, it has increased the failure rate of breast reconstruction after total mastectomy. Change of timing in breast reconstruction (immediate vs. two-staged by use of tissue expander) has not decreased the complications rate after PMRT. Currently the failure rate of breast reconstruction after total mastectomy and PMRT ranges from 0% to 40%. The present study will recruit 80 participants affected by breast cancer candidated to total mastectomy with immediate breast reconstruction and subsequent PMRT or total mastectomy with reconstruction by tissue expander, subsequent PMRT and then definitive reconstruction with breast implant. Participants will be randomized in two experimental arms: 40 patients will receive final reconstruction by the use of standard silicone-based breast implant and the other 40 patients will receive B-Lite® light weight breast implant. Participants will be followed up at 1, 6, 12 and 24 months, and all patients will undergo breast MRI at 6 months. The primary goal of the present study is to evaluate the failure rate of breast reconstruction (i.e. the need of re-intervention for breast implant removal). Secondary end-points include the overall complications rate, MRI evaluation of breast implant and surrounding tissues, cosmetic outcomes and quality of life including participants' satisfaction with breast reconstruction.

Condition or Disease Intervention/Treatment Phase
  • Device: B-Lite® light weight breast implant
  • Device: Standard silicone-based breast implant
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
80 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Standard Silicone-based Breast Implant vs. B-Lite® Light Weight Breast Implant for Reconstructive Surgery After Total Mastectomy and Post-Mastectomy Radiotherapy for Breast Cancer: a Randomized Clinical Trial
Actual Study Start Date :
Jun 1, 2018
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard silicone-based breast implant

Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of standard silicone-based breast implant (i.e. the breast implant commonly used in our institution)

Device: Standard silicone-based breast implant
Definitive breast reconstruction after total mastectomy by the use of silicone-based breast implants commonly used in our institution

Experimental: B-Lite® light weight breast implant

Participants candidated to total mastectomy and radiotherapy will receive immediate or delayed breast reconstruction by the use of B-Lite® light weight breast implant

Device: B-Lite® light weight breast implant
Definitive breast reconstruction after total mastectomy by the use of B-Lite® light weight breast implant

Outcome Measures

Primary Outcome Measures

  1. Failure rate of breast reconstruction [24 months]

    Need of re-intervention for breast implant removal for any cause (such as breast implant exposure)

Secondary Outcome Measures

  1. Overall complications rate [24 months]

    Occurrence of any complication at any time point, such as: capsular contracture, wound dehiscence, skin/soft tissues necrosis, inframammary fold break, implant exposure treated conservatively, hematoma, peri-prosthetic fluid collection, wound/implant infection

  2. Magnetic resonance imaging (MRI) of breast implant and surrounding tissues [6 months]

    MRI evaluation for skin/soft tissues thinning, capsular contracture, implant break, chronic seroma

  3. Change in cosmetic outcome [1, 6, 12, 24 months]

    Objective evaluation of cosmetic outcome by jugular-nipple/areola complex (NAC) and NAC-inframammary fold distances to evaluate symmetry, objective evaluation of plastic surgeon with serial photographs

  4. Change in Quality of life (QoL) measured with BIBCQ [6, 12, 24 months]

    QoL evaluation included patient's satisfaction with breast reconstruction using the Body Image after Breast Cancer Questionnaire (BIBCQ)

  5. Change in Quality of life (QoL) measured with BREAST-Q [6, 12, 24 months]

    QoL evaluation included patient's satisfaction with breast reconstruction, using the BREAST-Q score

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Breast cancer diagnosis with indication of total mastectomy and breast reconstruction

  • Indication of post-mastectomy radiation therapy

  • Availability to be followed up for 24 months

  • Signature of informed consent

Exclusion Criteria:
  • Patients candidated to breast-conserving surgery

  • Contraindicated breast reconstruction (severe comorbidities, unfavourable survival outcome expected, distant metastases)

  • Patients affected by other solid malignancies

  • Pregnancy

  • Participation to other clinical studies in the last three months

Contacts and Locations

Locations

Site City State Country Postal Code
1 Breast Unit - Istituti Clinici Scientifici Maugeri Spa SB Pavia Italy

Sponsors and Collaborators

  • Istituti Clinici Scientifici Maugeri SpA

Investigators

  • Principal Investigator: Fabio Corsi, MD, Istituti Clinici Scientifici Maugeri Spa SB

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Istituti Clinici Scientifici Maugeri SpA
ClinicalTrials.gov Identifier:
NCT03737500
Other Study ID Numbers:
  • ICS Maugeri - CE 2202
First Posted:
Nov 9, 2018
Last Update Posted:
Mar 31, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2022